Novartis (NOVN SW) Q4 (USD): Core EPS 2.03 (exp. 1.99), Revenue 13.3bln (exp. 13.7bln), guides initial FY26 revenue in the low single digit, core EPS declining by low single digits

Novartis reported a mixed Q4, beating core EPS expectations but falling short on revenue.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Hankook Tire & Technology (161390 KS) Q4 operating profit rose 16% Y/Y to KRW 548.3bln

Credit Agricole (ACA FP) Q4 (EUR): Net Income 1.03bln (exp. 1.1bln), Revenue 9.97bln (exp. 6.77bln)

Novartis (NOVN SW) Q4 (USD): Core EPS 2.03 (exp. 1.99), Revenue 13.3bln (exp. 13.7bln), guides initial FY26 revenue in the low single digit, core EPS declining by low single digits

Elon Musk's team conducted site visits to Chinese PV firms last week, including TCL Zhonghuan (002129 CH), Jinko Solar (JKS), and Jinggong Mechanical & Electrical, according to Cailian press

UBS (UBSG SW) Q4 (USD) Net Income 1.2bln (exp. 967mln), Pre-tax Profit 1.7bln (exp. 1.46bln), Investment Bank Pretax 640mln (exp. 468.7mln), Co. is to buyback USD 3bln of its own shares this year and aims to do more

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

CEO:

  • "In 2026, we expect to grow through the largest patent expiry in Novartis history, underscoring the strength of our business, and remain well on track to deliver our mid-term guidance.”
Context

The guidance for FY26 suggests a cautious outlook with low single-digit revenue growth and declining core EPS, which points to challenges from patent expiries. This mixed performance could pressure shares as investors react to the outlook amidst an important transition for the company.

Related headlines

The whole workspace, free to try.

Try it free